Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Canadian ALS Best Practice Recommendations
Neuromuscular and Clinical Neurophysiology (EMG)
P7 - Poster Session 7 (5:30 PM-6:30 PM)
1-007
Canadian ALS clinicians feel that it is important to develop best practice recommendations that could be used to set a national standard for management of Canadian patients living with ALS.  The guidelines would be an update to previously published guidelines and address several issues unique to Canada.  The recommendations would be supported by evidence or by Canadian expert consensus where evidence was unavailable.
Several ALS clinical practice guidelines have been published including the Âé¶¹´«Ã½Ó³»­ ALS Practice Parameters, EFNS ALS guidelines, and NICE Motor Neurone Disease guidelines.  There are no published Canadian ALS clinical guidelines. 

The guideline working group consisted of eleven Canadian ALS clinicians with geographic representation from across the country.  Clinical questions of interest were obtained by surveying clinicians and staff at all the Canadian ALS clinics, and then further refined by the working group.  Literature searches on the questions were conducted by a consulting firm (Centre for Effective Practice) with guideline development experience.   Medline, EMBASE, and CINHAL databases were searched.  Retrieved abstracts were screened for inclusion criteria, and selected publications were reviewed for relevance and data quality.  Guideline statements for each clinical question were developed on an iterative basis until consensus was obtained.  Finally, each guideline statement was assigned an evidence rating, which included the option of expert consensus.  Public feedback on the draft recommendations was elicited. 

Canadian ALS Best practice recommendations have been developed covering the topics of: 1) delivery of an ALS diagnosis, 2) disease related treatment, 3) multidisciplinary care, 4) respiratory management, 5) nutrition management, 6) DVT risk, 7) medication alignment, 8) symptom management, 9) dysarthria management, 10) exercise in ALS, 11) cognition, 12) caregiver burden and support, 13) palliative care, and 14) medical assistance in dying.  

These recommendations will serve to better support the clinical care and management of Canadian patients living with ALS. 
Authors/Disclosures
Christen L. Shoesmith, MD, BSc, FÂé¶¹´«Ã½Ó³»­ (University Hospital)
PRESENTER
The institution of Dr. Shoesmith has received research support from AL-Pharma. The institution of Dr. Shoesmith has received research support from Mitsubishi Tanabe. The institution of Dr. Shoesmith has received research support from Cytokinetics. The institution of Dr. Shoesmith has received research support from Sanofi. The institution of Dr. Shoesmith has received research support from Neurosense. The institution of Dr. Shoesmith has received research support from Regeneron. Dr. Shoesmith has a non-compensated relationship as a Canadian ALS Research Consortium Chair with ALS Canada that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Agessandro Abrahao, Jr., MD (Sunnybrook Health Sciences Centre - University of Toronto) Dr. Abrahao has nothing to disclose.
Timothy J. Benstead, MD No disclosure on file
Marvin C. Chum, MD (St. Joseph's Healthcare Hamilton - Neuro-Diagnostics) Dr. Chum has nothing to disclose.
No disclosure on file
Aaron E. Izenberg, MD (Sunnybrook Health Sciences Centre) Dr. Izenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Izenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Izenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Dr. Izenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexxion. Dr. Izenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for alnylam.
Wendy Johnston, MD, FRCP(C), FÂé¶¹´«Ã½Ó³»­ (Universtiy of Alberta) Dr. Johnston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Johnston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Inc.. Dr. Johnston has a non-compensated relationship as a Board Member with ALS Canada that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Johnston has a non-compensated relationship as a Chair with Canadian ALS Clinical Research Group that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Sanjay Kalra, MD (University of Alberta) The institution of Dr. Kalra has received research support from Brain Canada Foundation. The institution of Dr. Kalra has received research support from Biogen.
No disclosure on file
Colleen M. O'Connell, CNP (Ohio State University Medical Center) No disclosure on file
Kerri Schellenberg, MD No disclosure on file
No disclosure on file
Lorne H. Zinman, MD Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, MTP, AB Science, Cytokinetics, Amylyx. Dr. Zinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx.